Drugs / DSP107
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04937166 | Jan 2022 → Apr 2025 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Kahr Medical | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04440735 | Oct 2020 → Sep 2025 overdue | colorectal cancer, non-small cell lung carcinoma | Kahr Medical | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07235293 | Jan → Sep 2026 expected | colorectal cancer | Kahr Bio Australia Pty Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSP107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04937166 ↗ |
| Modality | Protein / enzyme biologic | “DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.” NCT04440735 ↗ |
| Route | Intravenous | “DSP107 will be administered by intravenous infusion over 1 hour” NCT04440735 ↗ |